fibrin and Eye-Diseases

The aim of our study is estimation of the efficacy of recombinant tissue plasminogen activator for the treatment of fibrinous membranes following cataract extraction.. The fibrinous membranes were formed, despite conventional antiinflammatory therapy, in 17 eyes after ECCE with IOL and in 3 eyes after ECCE without IOL. We injected the solution of recombinant tissue plasminogen activator-Actilyse (Boehringer Ingelheim) into the anterior chamber of 20 eyes after cataract surgery. Simultaneously, topical corticosteroid and cycloplegic therapy was continued. Routine follow-up included slit lamp examination, ophthalmoscopy and intraocular pressure measurement.. Injection of the solution of tissue plasminogen activator into anterior chamber of 20 eyes resulted in complete dissolution of the fibrinous membranes in 18 eyes within 1 day. In 7 eyes, within a few days after injection, fibrinous membrane recurred. In four of this cases durable effect of fibrin dissolution was obtained after multiple tPA injections. Finally, expectable stable result was obtained in 15 of 20 eyes.. Results of our study confirm high efficacy of recombinant tissue plasminogen activator in the treatment of fibrinous membranes after cataract surgery. Short term follow-up and small number of cases motivates further continuation of observation.

Topics: Aged; Aged, 80 and over; Anterior Chamber; Cataract Extraction; Exudates and Transudates; Eye Diseases; Female; Fibrin; Fibrinolysis; Humans; Injections; Male; Middle Aged; Plasminogen Activators; Recombinant Proteins; Recurrence; Tissue Plasminogen Activator

In a preliminary clinical study, recombinant tissue plasminogen activator (rt-PA) was injected into the anterior chamber of 18 eyes and into the vitreous cavity of 2 eyes in a total of 20 patients. The clinical indications were severe fibrin formation after filtering operations for glaucoma (8 eyes), diabetic neovascular glaucoma (3), fibrin and hemorrhage after vitrectomy (3), keratoplasty (3), posterior chamber lens implantation (1), trauma (1), and endophthalmitis (1). Complete fibrinolysis within a minimum of 2 h was achieved in 81% of 26 injections. Although doses of about 12 micrograms rt-PA were generally given, in our observations, 6 micrograms proved to be sufficient for rapid fibrinolysis in selected cases. Injections of rt-PA should not be considered before the 3rd postoperative day so as to avoid rebleeding and recurrent fibrin formation. No toxic intraocular side effect was observed after the use of rt-PA in this study.

Topics: Adult; Aged; Aged, 80 and over; Anterior Chamber; Eye Diseases; Female; Fibrin; Fibrinolysis; Humans; Injections; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Thrombolytic Therapy; Tissue Plasminogen Activator; Vitreous Body

Toxic anterior segment syndrome (TASS) is an acute, sterile, inflammatory reaction of the anterior segment after intraocular surgeries. We aimed to report an outbreak of TASS which occurred following pterygium surgeries.. A case series.. Four eyes of four patients developed TASS associated with formaldehyde after uneventful primary pterygium surgery with conjunctival autograft. No patients reported pain; all patients demonstrated diffuse corneal edema, epithelial defects, and anterior chamber inflammation without hypopyon, fibrin formation, and vitreous involvement on the first postoperative day. TASS diagnosis was made based on clinical findings. All patients were treated with hourly topical 1% prednisolone acetate (Pred Forte, Allergan, CA), moxifloxacin 0.5% (Vigamox, Alcon, TX), and 0.24% of hyaluronic acid (Artelac complete, Bausch & Lomb). Oral steroid (prednisolone 1 mg/kg) was added on the first week and gradually tapered over weeks. None of the affected corneas improved spontaneously. Best-corrected visual acuity ranged from 20/25000 to 20/200 in the second month after surgery. Keratoplasty was scheduled for all patients.. This is the first study to present TASS cases after pterygium surgery. Clinicians should be aware of TASS that can emerge after an extraocular surgery. In our analysis, since 2% formaldehyde was used by the operating room personnel for cleaning and sterilizing reusable ocular instruments, it was thought that formaldehyde was the most likely cause.

Topics: Anterior Eye Segment; Conjunctiva; Eye Diseases; Fibrin; Formaldehyde; Humans; Hyaluronic Acid; Moxifloxacin; Phacoemulsification; Postoperative Complications; Prednisolone; Pterygium; Syndrome

To evaluate the safety and efficacy of the surgical use of autologous plasma rich in growth factors fibrin membrane (mPRGF) in improving corneal wound healing and regeneration in a variety of complex ocular surface defects.. Chart review on 15 eyes of 14 included patients undergoing ocular surface intervention using intraoperative mPRGF at the Bascom Palmer Eye Institute and at the Instituto Oftalmológico Fernández-Vega was performed. Patients were grouped based on type of intervention or condition (penetrating keratoplasty, superficial keratectomy, neurotrophic or persistent corneal ulcers, and corneal perforation). Patients were followed for an average of 11 ± 5 months. Main outcomes measured were mPRGF dissolving time, best-corrected visual acuity, and evidence of any persistent epithelial defects, rejections, or complications.. All 15 eyes underwent successful placement of mPRGF. Average dissolving time for fibrin membrane was 21 ± 3 days. mPRGF resulted in total healing of the corneal defects in 13/15 (86.7%) of the treated eyes and partial healing in 2/15 (13.3%) eyes in which persistent epithelial defects were noted on follow-up. Visual acuity improvement was seen in 9/15 (60%) of the cases.. The use of autologous mPRGF in the healing and regeneration of the ocular surface is a secure and efficacious surgical option. Our data demonstrate that PRGF fibrin membrane should be contemplated as an important tool to optimize ocular surface regeneration in complex cases.

Topics: Corneal Diseases; Corneal Ulcer; Eye Diseases; Fibrin; Humans; Intercellular Signaling Peptides and Proteins; Wound Healing

To evaluate the safety and efficacy of the surgical use of plasma rich in growth factors fibrin membrane (mPRGF) in different ocular surface pathologies.Fifteen patients with different corneal and conjunctival diseases were included in the study. Patients were grouped according to the use of mPRGF as graft (corneal and/or conjunctival) or dressing; they were also grouped according to the surgical subgroup of intervention (persistent corneal ulcer [PCU], keratoplasty, superficial keratectomy, corneal perforation, and pterygium). Best corrected visual acuity, intraocular pressure (IOP), inflammation control time (ICT), mPRGF AT (PRGF membrane absorption time), and the healing time of the epithelial defect (HTED) were evaluated throughout the clinical follow-up time. Safety assessment was also performed reporting all adverse events.mPRGF showed a total closure of the defect in 13 of 15 patients (86.7%) and a partial closure in 2 patients (13.3%). The mean follow-up time was 11.1 ± 4.2 (4.8-22.8) months, the mean ICT was 2.5 ± 1.1 (1.0-4.0) months, the mean mPRGF AT was 12.4 ± 2.0 (10.0-16.0) days, and for the global HTED the mean was 2.9 ± 1.2 (1-4.8) months. Results showed an improvement in BCVA in all patients, with an overall improvement of 2.9 in Vision Lines. The BCVA significantly improved (P < .05) in the groups of corneal graft and dressing. In the PCU subgroup (6 patients), the healing time of epithelial defect was significantly reduced (P < .05) in patients treated only with the mPRGF in comparison to those which mPRGF therapy was associated to the amniotic membrane. The IOP remained stable (P > .05) throughout the clinical follow-up time. No adverse events were reported after mPRGF use.The mPRGF is effective and safe as coadjuvant treatment in surgeries related with ocular surface disorders, being an alternative to the use of amniotic membrane. The mPRGF accelerates tissue regeneration after ocular surface surgery thus minimizing inflammation and fibrosis.

Topics: Aged; Aged, 80 and over; Amnion; Biological Dressings; Eye Diseases; Female; Fibrin; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Ophthalmologic Surgical Procedures; Platelet-Rich Plasma; Retrospective Studies; Tissue Transplantation; Visual Acuity

Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Eye Diseases; Fibrin; Humans; Laser Coagulation; Macular Edema; Male; Middle Aged; Postoperative Complications; Tomography, Optical Coherence; Vitrectomy; Vitreous Body; Vitreous Hemorrhage

To evaluate the efficacy and safety of tissue plasminogen activator in management of postoperative fibrinous uveitis.. Prospective study, interventional case series including 13 patients who developed fibrinous membrane in anterior chamber; patients were operated for cataract (4 cases), for cataract and glaucoma (7 cases) and for corneoscleral lacerations (2 cases). Initial treatment consisted of corticosteroid administration (topically, subconjunctival +/- systemic) and mydriatic-cycloplegic drugs. Inadequate response imposed intracavitary administration of tissue plasminogen activator (25 microg/ml, 0.2 ml). The main outcomes were: complete resolution of fibrinous membrane, presence of adverse events and visual rehabilitation.. Fibrinous membrane resorption starts in the next hours and complete resolution was proved in all cases after a mean time 53.55 +/- 37.65 (24-146) hours. In 12 patients we used only one administration of tissue plasminogen activator, but in one case we repeated it. It was not signaled any adverse event drug related. It was an important increase of visual acuity in all cases.. Intracavitary administration of tissue plasminogen activator is a safe and efficient alternative in the management of postoperative fibrinous membrane.

Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Algorithms; Cataract Extraction; Drug Therapy, Combination; Eye Diseases; Female; Fibrin; Fibrinolytic Agents; Humans; Injections, Intralesional; Male; Middle Aged; Postoperative Complications; Prospective Studies; Tissue Plasminogen Activator; Uveitis; Visual Acuity

To determine the efficacy of topical tissue plasminogen activator (tPA) for the resolution of postoperative or inflammatory intraocular fibrinous exudates.. Each treatment consisted of drops of 1 mg/ml tPA given 9 times 5 minutes apart. Records were reviewed and the results at 24 and 48 hours were recorded. Sixty-two patients had a total of 94 treatments.. Fibrin exudates following intraocular surgery in 34 patients were treated 44 times. In 6 patients there was a positive result. Fibrin associated with intraocular infection was treated in 9 patients. None showed clear improvement. Nineteen patients had a total of 34 treatments for poorly controlled intraocular pressure (IOP) after glaucoma surgery. Five patients showed adequate control of the IOP, 12 did not change, and 2 had a questionable improvement. Eleven patients had adequate IOP control after additional treatment. Seven required suture lysis, 2 ab interno bleb revision, and 2 YAG capsulotomy or iridotomy to reduce the IOP to an acceptable level.. Within the limits of this retrospective study and taking into account that fibrin may resolve spontaneously, it appears that topical tPA drops are not effective for the liquefaction of intraocular fibrin after surgery or in association with intraocular inflammation. They did not improve IOP control after glaucoma surgery.

Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Eye Diseases; Female; Fibrin; Fibrinolysis; Follow-Up Studies; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmologic Surgical Procedures; Plasminogen Activators; Postoperative Complications; Retrospective Studies; Tissue Plasminogen Activator; Treatment Outcome

Recombinant tissue plasminogen activator (rTPA) is commonly used in patients with myocardial infarction. Recently, it has also been applied intraocularly to dissolve postoperative fibrin with no serious complications being reported so far. In this study we describe our own experience with rTPA in 25 patients with persisting fibrinous membranes in the anterior segment. rTPA (Actilyse, Dr. Karl Thomae GmbH) was given in a single dose of 25 micrograms and injected into the anterior chamber via a paracentesis. We did not encounter any complications during the injection of rTPA. In 21 eyes fibrin could be reduced significantly, albeit sometimes only slowly. In 13 patients, the membrane had dissolved almost completely by the following day. In contrast, no success was observed after glaucoma surgery (2 eyes) and in chronic iritis (1 eye), or when fibrin mixed with blood was treated (1 eye). There were two (controllable) post-operative hemorrhages (rTPA after vitrectomy, and for fibrin/blood after cataract surgery). In addition, we noted 2 cases of irreversible superficial corneal clouding (rTPA after cataract surgery). We conclude that injection of rTPA can be a useful addition to steroid treatment in selective cases of persisting fibrin in the anterior segment. Long-standing membranes, however, are unlikely to be dissolved. Care should also be taken and rTPA be avoided when there is evidence of recent bleeding. Most worrying to us were the corneal complications that we cannot explain to date. With regard to the definite time correlation we feel that rTPA or one of the solution components might be the cause of this unusual feature.

Topics: Anterior Eye Segment; Eye Diseases; Fibrin; Humans; Injections; Paracentesis; Postoperative Complications; Thrombolytic Therapy; Tissue Plasminogen Activator; Visual Acuity

Tissue plasminogen activator (tPA) has been used to treat severe postcataract and vitrectomy fibrinous membranes, but intraocular bleeding has occurred with doses of 25 micrograms or higher. We report three patients, one with nonclearing total hyphema and uncontrollable intraocular pressure and two with severe fibrinous membrane formation, who had treatment with low-dose (4 micrograms to 6 micrograms) intraocular tPA. Although the fibrinous membranes or hyphema resolved in all three patients, they recurred and bleeding that required additional treatment occurred in one patient. Intraocular low-dose tPA may minimize the risk of corneal and retinal toxicity and may be considered an alternative treatment in intractable cases. However, secondary intraocular hemorrhage can occur, and the timing between the initial vascular injury, treatment with tPA, and subsequent bleeding may reduce the risk of further hemorrhaging.

Topics: Adult; Aged; Anterior Chamber; Cataract Extraction; Child; Cornea; Corneal Injuries; Eye Diseases; Eye Injuries, Penetrating; Fibrin; Humans; Hyphema; Injections; Keratoplasty, Penetrating; Male; Postoperative Complications; Recombinant Proteins; Tissue Plasminogen Activator

We report on our first two patients treated by intracameral application of tissue plasminogen activator (tPA) for dissolving fibrinous exsudates. Both patients had developed fibrin membranes in the pupillary plane and in the anterior chamber several days after cataract surgery. Injection of 25 micrograms tPA into the anterior chamber resulted in complete dissolution of the fibrin within 1 h of its application.

Topics: Aged; Anterior Chamber; Cataract Extraction; Exudates and Transudates; Eye Diseases; Female; Fibrin; Fibrinolysis; Humans; Injections; Postoperative Complications; Recombinant Proteins; Tissue Plasminogen Activator

To determine whether postvitrectomy fibrin formation was associated with visual outcome, a prospective study of patients undergoing pars plana vitrectomy was performed.. In 121 patients undergoing vitrectomy at the Medical College of Wisconsin between July 1986 and April 1989, the association of fibrin formation and other perioperative factors with visual outcome was evaluated by univariate and multivariate regression analysis. Poor visual outcome was defined as visual acuity worse than 5/200.. After a median follow-up period of 23 months (range 6 to 51 months), patients with severe fibrin formation experienced a higher rate of poor visual outcome (19 of 26 patients, 73%) than patients with little or no fibrin formation (23 of 95 patients, 24%; P < 0.0001, univariate analysis). After adjusting for a variety of factors with multivariate regression analysis, fibrin formation was not significantly predictive of final visual outcome.. Factors associated with postvitrectomy fibrin formation may affect visual outcome more than fibrin formation itself.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Eye Diseases; Fibrin; Follow-Up Studies; Humans; Middle Aged; Postoperative Complications; Prognosis; Tissue Plasminogen Activator; Visual Acuity; Vitrectomy

Three patients who developed anterior chamber fibrinous exudates after cataract surgery were treated with tissue plasminogen activator injected into the anterior chamber. There was prompt dissolution of the fibrinous exudates and no observed complications. When fibrinous exudates occur in high-risk patients after cataract surgery, tissue plasminogen activator provides an excellent means of clearing the fibrin.

Topics: Adult; Aged; Anterior Chamber; Cataract Extraction; Exudates and Transudates; Eye Diseases; Female; Fibrin; Humans; Lenses, Intraocular; Male; Postoperative Complications; Recombinant Proteins; Tissue Plasminogen Activator

We developed a new dilution technique that allows tissue plasminogen activator (t-PA) to be stored at -20 degrees C, as opposed to the -70 degrees C recommended by the United States manufacturer (Genentech Inc). Following tests that showed neither loss in activity nor microbiological contamination, we clinically proved the efficacy of t-PA stored at -20 degrees C in 10 cases.

Topics: Cryopreservation; Drug Storage; Eye Diseases; Fibrin; Humans; Microbiological Techniques; Thrombolytic Therapy; Tissue Plasminogen Activator

We report a patient who developed severe intraocular fibrin formation following penetrating keratoplasty and vitrectomy surgery. The fibrin response worsened despite aggressive treatment with topical steroids. On the second postoperative day, 25 micrograms of intracameral tissue plasminogen activator was administered, resulting in rapid resolution of the fibrin response. The graft remained clear. We believe tissue plasminogen activator may be useful in selected cases of severe, recalcitrant postkeratoplasy fibrin formation.

Topics: Eye Diseases; Female; Fibrin; Fibrosis; Humans; Keratoplasty, Penetrating; Middle Aged; Tissue Plasminogen Activator; Vitrectomy

Human recombinant tissue plasminogen activator (25 micrograms) was injected into seven eyes of six patients who had developed massive fibrin deposition after vitrectomy surgery for diabetes. Six eyes had developed pupillary membranes and recurrence of tractional retinal detachment from fibrin membranes, and one eye had developed only a pupillary membrane. All pupillary membranes resolved within one hour of administration of tissue plasminogen activator, and five tractional retinal detachments resolved within 24 hours. All eyes developed evidence of intraocular bleeding after tissue plasminogen activator injection. Subsequently, six of seven eyes developed recurrence of fibrin accumulation and tractional retinal detachment.

Topics: Adult; Diabetic Retinopathy; Eye Diseases; Female; Fibrin; Hemorrhage; Humans; Male; Middle Aged; Postoperative Care; Postoperative Complications; Retinal Detachment; Tissue Plasminogen Activator; Vitrectomy

Topics: Eye Diseases; Fibrin; Humans; Recombinant Proteins; Tissue Plasminogen Activator; Vitrectomy

We prospectively studied 194 patients undergoing vitrectomy between July 1988 and April 1989 to determine the incidence of postvitrectomy intraocular fibrin formation and the association of a variety of preoperative and intraoperative variables with the formation of severe postvitrectomy fibrin. Overall, 62 (32%) patients developed postvitrectomy fibrin; 25 (13%) had mild fibrin formation, 13 (6.5%) had moderate fibrin formation, and 24 (12.4%) had severe fibrin formation. By logistic multivariate analysis, preoperative factors that were independently predictive of severe fibrin formation included severe flare (P = .004), the presence of a previously placed scleral buckle (P = .001), and poor preoperative visual acuity (P = .007). Anterior epiretinal membrane dissection was the only intraoperative factor that was independently associated with an increased fibrin risk (P = .0003). A risk score derived from the multivariate analysis effectively categorized patients according to their likelihood of developing severe postvitrectomy fibrin. Results of this study may be useful in designing prophylactic interventions to decrease postvitrectomy fibrin formation.

Topics: Adult; Aged; Chi-Square Distribution; Eye Diseases; Female; Fibrin; Humans; Incidence; Intraoperative Complications; Male; Middle Aged; Multivariate Analysis; Postoperative Care; Preoperative Care; Prospective Studies; Risk Factors; Scleral Buckling; Visual Acuity; Vitrectomy

A transitory deposit of a fibrin-like material in the anterior chamber following extracapsular cataract extraction and intraocular lens (IOL) implantation is described. In two studies, one retrospective of 352 operations and one prospective of 189 operations, the fibrinoid reaction was observed in 17% and 11% of the eyes, respectively. The reaction appeared in the early postoperative period in an otherwise quiet eye and the signs varied from a few threads in the pupil area to a dense pupillary membrane in front of the IOL. The deposit disappeared one day to three weeks postoperatively, usually without any remnants. The majority of eyes with the fibrinoid reaction had received a posterior chamber IOL. A strong association with the exfoliation syndrome was found and an increased vascular permeability is suggested as a probable cause of the reaction.

Topics: Aged; Anterior Eye Segment; Cataract Extraction; Eye Diseases; Female; Fibrin; Humans; Lenses, Intraocular; Prospective Studies; Retrospective Studies; Syndrome

Twenty-five micrograms of human recombinant tissue plasminogen activator (tPA) was injected intracamerally into the eyes of three aphakic patients who developed severe intraocular fibrin formation within 24 hours after vitrectomy surgery. Fluid obtained from gas-fluid exchange specimens taken 24 hours after tPA injection was analyzed for tPA by an enzyme-linked immunosorbent assay and a spectrophotometric solid-phase fibrin assay. In each of the three patients, complete fibrin resolution occurred within four hours after the tPA injection. There were no complications associated with the intraocular tPA injections. There was measurable tPA activity 24 hours after the initial injection ranging from 0.23 to 1.4 micrograms. In contrast, tPA was undetectable in gas-fluid exchange specimens obtained from seven patients who did not receive intraocular tPA injections. Intraocular tPA is an effective means of treating postvitrectomy fibrin formation in selected aphakic patients.

Topics: Adolescent; Adult; Anterior Chamber; Eye Diseases; Female; Fibrin; Fibrinolysis; Humans; Injections; Male; Middle Aged; Postoperative Complications; Tissue Plasminogen Activator; Vitrectomy

Topics: Anterior Eye Segment; Conjunctiva; Cornea; Eye Diseases; Fibrin; Fistula; Humans; Microsurgery; Sclera; Tissue Adhesives; Wound Healing

Topics: Animals; Eye; Eye Diseases; Fibrin; Hemorrhage; Rabbits; Time Factors

Two hundred eighty consecutive vitrectomies in diabetic patients were studied retrospectively. In 15 eyes, interlacing fibrin-like strands appeared on the surface of the retina and behind the iris plane from two to 14 days postoperatively. One or two days later, a gelatinous mass formed in the center of the vitreous activity, leading to the development of tractional retinal detachment and rubeosis iridis with neovascular glaucoma. Large doses of systemic and topical corticosteroids reversed the fulminating course of this complication in six of 15 eyes. The combination of lens surgery or scleral buckling procedure with vitrectomy, and the presence of retinal detachment preoperatively seemed to predispose to this complication. It is possible that multiple surgical procedures performed during the same operation cause an increase in vascular permeability resulting in the formation of a gelatinous, fibrin-like material in the diabetic eye.

Topics: Adult; Aged; Diabetic Retinopathy; Eye Diseases; Female; Fibrin; Glaucoma; Humans; Intraocular Pressure; Iris Diseases; Male; Middle Aged; Postoperative Complications; Retinal Detachment; Retrospective Studies; Syndrome; Vitreous Body

Subtotal open-sky vitrectomy can be used to improve visual function in some eyes for which closed vitrectomy is useless. Open-sky vitrectomy allows easier access for surgical instruments, especially to anterior fundus structures. The technique also improves the visibility of intraocular structures. The surgical procedure, which uses special instruments and high-molecular-weight hyaluronic acid, is divided into four stages: preparation, operating inside the vitreous cavity, wound closure, and retinal reattachment. In 290 consecutive operations for which complete follow-up data are available, retinal reattachment was achieved in 61 eyes (21%). The greatest number of successes (16 of 30 cases [53%]) was achieved in severe tractional retinal detachments. Such results are encouraging because these eyes were considered inoperable by other techniques. Open-sky vitreous surgery is performed through a corneal incision, but a scleral incision over the pars plana may become the method of choice in selected cases. The development of a preretinal fibrin membrane, as a result of either a closed vitrectomy or an open-sky procedure, may be a major cause of postoperative failure. Hypotony during surgery is probably the main precipitating factor of intraocular fibrin membrane formation.

Topics: Adolescent; Adult; Cataract; Child; Child, Preschool; Eye Diseases; Eye Foreign Bodies; Eye Injuries; Female; Fibrin; Humans; Lens Subluxation; Male; Middle Aged; Retinal Detachment; Scleral Buckling; Vitreous Body

This study confirms preliminary indications that dry-pack sterilized lenses cause a more marked anterior chamber reaction than wet-pack sterilized lenses during the immediate post-op period. After the first two weeks, this difference is not evident.

Topics: Aged; Anterior Chamber; Corneal Diseases; Edema; Ethylene Oxide; Eye Diseases; Female; Fibrin; Humans; Intraocular Pressure; Lenses, Intraocular; Male; Middle Aged; Postoperative Complications; Sodium Hydroxide; Sterilization; Time Factors; Visual Acuity

Topics: Animals; Cell Membrane; Cell Nucleus; Ciliary Body; Cytoplasm; Eye Diseases; Fibrin; Hemorrhage; Microscopy, Electron; Pigment Epithelium of Eye; Rabbits; Thrombocytopenia

Topics: Adult; Aged; Biocompatible Materials; Connective Tissue; Dermatologic Surgical Procedures; Eye Diseases; Female; Fibrin; Humans; Male

Complete inhibition of vitreous fibrinolytic activity with 4-amino-methylcyclohexane carbonic acid was associated with significantly delayed resolution of vitreous hemorrhages in rabbits. However, polyacrylamide gel electrophoresis indicated but a slight delay in the removal of the fibrin component of vitreous clots, and most of the residual vitreous opacity comprised intact red blood cells. Fibrin degradation products may act as chemotactic agents, promoting the removal of red blood cells by leukocytes; hence, their absence in treated rabbits might explain in part the delayed red blood cell clearance.

Topics: Absorption; Animals; Chemotaxis, Leukocyte; Cyclohexanecarboxylic Acids; Erythrocytes; Eye Diseases; Fibrin; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Hemorrhage; Phagocytosis; Rabbits; Tranexamic Acid; Vitreous Body

Topics: Animals; Eye Diseases; Fibrin; Fibrin Fibrinogen Degradation Products; Fibrinolysis; Hemolysis; Hemorrhage; Plasminogen Activators; Rabbits; Vitreous Body

We wished to know if excision of artificially produced intravitreal vessels would cause bleeding and if the hemorrhage could be controlled by increasing the intraocular pressure. In 17 rabbit eyes, the distal end of several intravitreal blood vessels was excised and removed by the Peyman vitrophage. No significant bleeding occurred from the vessels in 13 eyes, and in the remaining four bleeding stopped after 30 seconds or less of increased intraocular pressure. In one month of observation after surgery, there was no evidence of delayed hemorrhage. Electron microscopy of several transected intravitreal vessels revealed that vessel constriction, platelets and fibrin strands contributed to the prevention of immediate and delayed hemorrhage.

Topics: Ammonium Chloride; Animals; Disease Models, Animal; Endothelium; Erythrocytes; Eye Diseases; Fibrin; Hemorrhage; Hemostasis; Intraocular Pressure; Microscopy, Electron; Postoperative Complications; Rabbits; Retinal Diseases; Retinal Vessels; Time Factors; Vitreous Body

Topics: Aged; Anti-Bacterial Agents; Conjunctiva; Eosinophils; Eye Diseases; Eye Foreign Bodies; Eyelids; Female; Fibrin; Humans; Leukocytes; Male; Membranes; Middle Aged; Staining and Labeling

Topics: Animals; Behcet Syndrome; Collagen; Collagen Diseases; Cornea; Eye; Eye Diseases; Fibrin; Fibrinogen; Fluorescent Antibody Technique; Glaucoma; Humans; Rabbits; Uveitis

Topics: Anemia, Aplastic; Child; Eye Diseases; Female; Fibrin; Hemorrhage; Humans; Retina; Retinal Detachment; Retinal Hemorrhage; Vitreous Body